Emerging delivery systems to reduce doxorubicin cardiotoxicity and improve therapeutic index: Focus on liposomes

Anti-Cancer Drugs

Volumn 26, Issue 3, 2015, Pages 241-258

  Tahover, Esther ^a   Patil, Yogita P ^a   Gabizon, Alberto A ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

cancer; cardiotoxicity; doxorubicin; drug delivery systems; liposome; polymer

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DOXORUBICIN; EPIRUBICIN; LIPOSOME; MITOXANTRONE; NONPEGYLATED LIPOSOME ENCAPSULATED DOXORUBICIN; TRASTUZUMAB; UNCLASSIFIED DRUG; ANTHRACYCLINE; ANTINEOPLASTIC ANTIBIOTIC; CARDIOTONIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; MACROGOL DERIVATIVE; MONOCLONAL ANTIBODY;

ALOPECIA; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CARDIOVASCULAR RISK; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; DRUG EFFICACY; FOLLOW UP; HAND FOOT SYNDROME; HEART PROTECTION; HUMAN; INFUSION; KAPOSI SARCOMA; LIPOSOMAL DELIVERY; META ANALYSIS (TOPIC); MOUTH SQUAMOUS CELL CARCINOMA; MULTIPLE MYELOMA; NEPHROTOXICITY; NONHUMAN; OVARY CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POLYMERIZATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STOMATITIS; ANALOGS AND DERIVATIVES; DRUG DELIVERY SYSTEM; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PROCEDURES; RISK FACTOR;

ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; ANTIBODIES, MONOCLONAL, HUMANIZED; CARDIOTONIC AGENTS; CARDIOTOXICITY; DOXORUBICIN; DRUG DELIVERY SYSTEMS; HUMANS; LIPOSOMES; MOLECULAR TARGETED THERAPY; NEOPLASMS; POLYETHYLENE GLYCOLS; RECEPTOR, ERBB-2; RISK FACTORS;

EID: 84925490767     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0000000000000182     Document Type: Review

References (146)

1. Young RC, Ozols RF, Myers CE. The anthracycline antineoplastic drugs. N Engl J Med 1981; 305:139-153
2. Chatterjee K, Zhang J, Honbo N, Karliner JS. Doxorubicin cardiomyopathy. Cardiology 2010; 115:155-162
3. Kiyomiya K-I, Matsuo S, Kurebe M. Mechanism of specific nuclear transport of adriamycin the mode of nuclear translocation of adriamycin-proteasome complex. Cancer Res 2001; 61:2467-2471
4. Frederick CA, Williams LD, Ughetto G, Van Der Marel GA, Van Boom JH, Rich A, et al. Structural comparison of anticancer drug-DNA complexes: Adriamycin and daunomycin. Biochemistry 1990; 29:2538-2549
5. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines:molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004; 56:185-229
6. Ashley N, Poulton J. Mitochondrial DNA is a direct target of anti-cancer anthracycline drugs. Biochem Biophys Res Commun 2009; 378:450-455
7. Gewirtz DA. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 1999; 57:727-741
8. Hortobagyi GN. Anthracyclines in the treatment of cancer. An overview. Drugs 1997; 54 (Suppl 4):1-7
9. Smith RE, Bryant J, DeCillis A, Anderson S. Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience. J Clin Oncol 2003; 21:1195-1204
10. Singal PK, Iliskovic N, Li T, Kumar D. Adriamycin cardiomyopathy:pathophysiology and prevention. FASEB J 1997; 11:931-936
11. Bauch M, Ester A, Kimura B, Victorica BE, Kedar A, Phillips MI. Atrial natriuretic peptide as a marker for doxorubicin-induced cardiotoxic effects. Cancer 1992; 69:1492-1497
12. Davies KJ, Doroshow JH. Redox cycling of anthracyclines by cardiac mitochondria. I. Anthracycline radical formation by NADH dehydrogenase. J Biol Chem 1986; 261:3060-3067
13. Kotamraju S, Konorev EA, Joseph J, Kalyanaraman B. Doxorubicin-induced apoptosis in endothelial cells and cardiomyocytes is ameliorated by nitrone spin traps and ebselen. Role of reactive oxygen and nitrogen species. J Biol Chem 2000; 275:33585-33592
14. Kotamraju S, Kalivendi SV, Konorev E, Chitambar CR, Joseph J, Kalyanaraman B. Oxidant-induced iron signaling in doxorubicin-mediated apoptosis. Methods Enzymol 2004; 378:362-382
15. Dowd NP, Scully M, Adderley SR, Cunningham AJ, Fitzgerald DJ. Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo. J Clin Invest 2001; 108:585-590
16. Milic Torres V, Dragojevic Simic V. Doxorubicin-induced oxidative injury of cardiomyocytes - do we have right strategies for prevention? In: Fiuza M, editor. Cardiotoxicity of oncologic treatments. Rijeka, Croatia, INTECH, 2012. pp. 89-130
17. Sakata Y, Dong JW, Vallejo JG, Huang CH, Baker JS, Tracey KJ, et al. Tolllike receptor 2 modulates left ventricular function following ischemiareperfusion injury. Am J Physiol Heart Circ Physiol 2007; 292:H503-H509
18. Shi Y, Moon M, Dawood S, McManus B, Liu PP. Mechanisms and management of doxorubicin cardiotoxicity. Herz 2011; 36:296-305
19. Von Hoff DD, Rozencweig M, Layard M, Slavik M, Muggia FM. Daunomycininduced cardiotoxicity in children and adults. A review of 110 cases. Am J Med 1977; 62:200-208
20. Carvalho FS, Burgeiro A, Garcia R, Moreno AJ, Carvalho RA, Oliveira PJ. Doxorubicin-induced cardiotoxicity: from bioenergetic failure and cell death to cardiomyopathy. Med Res Rev 2013; 34:106-135
21. Von Hoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, Rozencweig M, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91:710-717
22. Volkova M, Russell R 3rd. Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment. Curr Cardiol Rev 2011; 7:214-220
23. Alexander J, Dainiak N, Berger HJ, Goldman L, Johnstone D, Reduto L, et al. Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography. N Engl J Med 1979; 300:278-283
24. Buzdar AU, Marcus C, Smith TL, Blumenschein GR. Early and delayed clinical cardiotoxicity of doxorubicin. Cancer 1985; 55:2761-2765
25. Smith LA, Cornelius VR, Plummer CJ, Levitt G, Verrill M, Canney P, et al. Cardiotoxicity of anthracycline agents for the treatment of cancer:systematic review and meta-analysis of randomised controlled trials. BMC cancer 2010; 10:337
26. Bristow MR, Mason JW, Billingham ME, Daniels JR. Dose-effect and structure-function relationships in doxorubicin cardiomyopathy. Am Heart J 1981; 102:709-718
27. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003; 97:2869-2879
28. Berardi R, Caramanti M, Savini A, Chiorrini S, Pierantoni C, Onofri A, et al. State of the art for cardiotoxicity due to chemotherapy and to targeted therapies: a literature review. Crit Rev Oncol Hematol 2013; 88:75-86
29. Van Dalen EC, Van Der Pal HJ, Kok WE, Caron HN, Kremer LC. Clinical heart failure in a cohort of children treated with anthracyclines: a long-term follow-up study. Eur J Cancer 2006; 42:3191-3198
30. Mulrooney DA, Yeazel MW, Kawashima T, Mertens AC, Mitby P, Stovall M, et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ 2009; 339:b4606
31. Billingham ME, Mason JW, Bristow MR, Daniels JR. Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep 1978; 62:865-872
32. Bristow MR, Mason JW, Billingham ME, Daniels JR. Doxorubicin cardiomyopathy: evaluation by phonocardiography, endomyocardial biopsy, and cardiac catheterization. Ann Intern Med 1978; 88:168-175
33. Lu P. Monitoring cardiac function in patients receiving doxorubicin. Semin Nucl Med 2005; 35:197-201
34. Umlauf J, Horky M. Molecular biology of doxorubicin-induced cardiomyopathy. Exp Clin Cardiol 2002; 7:35-39
35. Posner LE, Dukart G, Goldberg J, Bernstein T, Cartwright K. Mitoxantrone: An overview of safety and toxicity. Invest New Drugs 1985; 3:123-132
36. Kalay N, Basar E, Ozdogru I, Er O, Cetinkaya Y, Dogan A, et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol 2006; 48:2258-2262
37. Seifert CF, Nesser ME, Thompson DF. Dexrazoxane in the prevention of doxorubicin-induced cardiotoxicity. Ann Pharmacother 1994; 28:1063-1072
38. Van Dalen EC, Caron HN, Dickinson HO, Kremer LC. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev 2011; Issue 6, Art. No.: CD003917
39. Sagnella SM, Duong HT, Macmillan A, Boyer C, Whan RM, McCarroll JA, et al. Dextran based doxorubicin nanocarriers with improved tumour penetration. Biomacromolecules 2013; 15:262-275
40. Jeong Y-I, Do Hyung Kim C-WC, Yoo J-J, Choi KH, Kim CH, Ha SH, et al. Doxorubicin-incorporated polymeric micelles composed of dextran-b-poly (DL-lactide-co-glycolide) copolymer. Int J Nanomedicine 2011; 6:1415-1427
41. Wohlfart S, Khalansky AS, Gelperina S, Maksimenko O, Bernreuther C, Glatzel M, et al. Efficient chemotherapy of rat glioblastoma using doxorubicin-loaded PLGA nanoparticles with different stabilizers. PloS One 2011; 6:e19121
42. Mitra S, Gaur U, Ghosh PC, Maitra AN. Tumour targeted delivery of encapsulated dextran-doxorubicin conjugate using chitosan nanoparticles as carrier. J Control Release 2001; 74:317-323
43. Susa M, Iyer A, Ryu K, Hornicek F, Mankin H, Amiji M, et al. Doxorubicin loaded polymeric nanoparticulate delivery system to overcome drug resistance in osteosarcoma. BMC cancer 2009; 9:399
44. Zhang P, Ling G, Pan X, Sun J, Zhang T, Pu X, et al. Novel nanostructured lipid-dextran sulfate hybrid carriers overcome tumor multidrug resistance of mitoxantrone hydrochloride. Nanomedicine 2012; 8:185-193
45. Hao H, Ma Q, Huang C, He F, Yao P. Preparation, characterization, and in vivo evaluation of doxorubicin loaded BSA nanoparticles with folic acid modified dextran surface. Int J Pharm 2013; 444:77-84
46. Tan ML, Choong PFM, Dass CR. Review: doxorubicin delivery systems based on chitosan for cancer therapy. J Pharm Pharmacol 2009; 61:131-142
47. Tan ML, Friedhuber AM, Dunstan DE, Choong PFM, Dass CR. The performance of doxorubicin encapsulated in chitosan-dextran sulphate microparticles in an osteosarcoma model. Biomaterials 2010; 31:541-551
48. Betancourt T, Brown B, Brannon-Peppas L. Doxorubicin-loaded PLGA nanoparticles by nanoprecipitation: preparation, characterization and in vitro evaluation. Nanomedicine 2007; 2:219-232
49. Danhauser-Riedl S, Hausmann E, Schick H-D, Bender R, Dietzfelbinger H, Rastetter J, et al. Phase I clinical and pharmacokinetic trial of dextran conjugated doxorubicin (AD-70, DOX-OXD). Invest New Drugs 1993; 11:187-195
50. Vasey PA, Kaye SB, Morrison R, Twelves C, Wilson P, Duncan R, et al. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl) methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents - drug-polymer conjugates. Clin Cancer Res 1999; 5:83-94
51. Duncan R, Seymour LW, O'Hare KB, Flanagan PA, Wedge S, Hume IC, et al. Preclinical evaluation of polymer-bound doxorubicin. J Control Release 1992; 19:331-346
52. Seymour LW, Ferry DR, Anderson D, Hesslewood S, Julyan PJ, Poyner R, et al. Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. J Clin Oncol 2002; 20:1668-1676
53. Seymour LW, Ferry DR, Kerr DJ, Rea D, Whitlock M, Poyner R, et al. Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer. Int J Oncol 2009; 34:1629-1636
54. Veronese FM, Schiavon O, Pasut G, Mendichi R, Andersson L, Tsirk A, et al. PEG-doxorubicin conjugates: influence of polymer structure on drug release, in vitro cytotoxicity, biodistribution, and antitumor activity. Bioconjug Chem 2005; 16:775-784
55. Kataoka K, Harada A, Nagasaki Y. Block copolymer micelles for drug delivery: design, characterization and biological significance. Adv Drug Deliv Rev 2012; 64:37-48
56. Kazunori K, Glenn SK, Masayuki Y, Teruo O, Yasuhisa S. Block copolymer micelles as vehicles for drug delivery. J Control Release 1993; 24:119-132
57. Kwon G, Suwa S, Yokoyama M, Okano T, Sakurai Y, Kataoka K. Enhanced tumor accumulation and prolonged circulation times of micelle-forming poly (ethylene oxide-aspartate) block copolymer-adriamycin conjugates. J Control Release 1994; 29:17-23
58. Yokoyama M, Fukushima S, Uehara R, Okamoto K, Kataoka K, Sakurai Y, et al. Characterization of physical entrapment and chemical conjugation of adriamycin in polymeric micelles and their design for in vivo delivery to a solid tumor. J Control Release 1998; 50:79-92
59. Kataoka K, Matsumoto T, Yokoyama M, Okano T, Sakurai Y, Fukushima S, et al. Doxorubicin-loaded poly(ethylene glycol)-poly(?-benzyl-l-aspartate) copolymer micelles: their pharmaceutical characteristics and biological significance. J Control Release 2000; 64:143-153
60. Kwon G, Naito M, Yokoyama M, Okano T, Sakurai Y, Kataoka K. Physical entrapment of adriamycin in AB block copolymer micelles. Pharm Res 1995; 12:192-195
61. Kwon G, Naito M, Yokoyama M, Okano T, Sakurai Y, Kataoka K. Block copolymer micelles for drug delivery: loading and release of doxorubicin. J Control Release 1997; 48:195-201
62. Lee ES, Na K, Bae YH. Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor. J Control Release 2005; 103:405-418
63. Kim D, Lee ES, Oh KT, Gao ZG, Bae YH. Doxorubicin-loaded polymeric micelle overcomes multidrug resistance of cancer by double-targeting folate receptor and early endosomal pH. Small 2008; 4:2043-2050
64. Ta HT, Dass CR, Larson I, Choong PFM, Dunstan DE. A chitosan-dipotassium orthophosphate hydrogel for the delivery of doxorubicin in the treatment of osteosarcoma. Biomaterials 2009; 30:3605-3613
65. Ta HT, Han H, Larson I, Dass CR, Dunstan DE. Chitosan-dibasic orthophosphate hydrogel: a potential drug delivery system. Int J Pharm 2009; 371:134-141
66. Kratz F. DOXO-EMCH (INNO-206): the first albumin-binding prodrug of doxorubicin to enter clinical trials. Expert Opin Investig Drugs 2007; 16:855-866
67. Unger C, Häring B, Medinger M, Drevs J, Steinbild S, Kratz F, et al. Phase I and pharmacokinetic study of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin. Clin Cancer Res 2007; 13:4858-4866
68. Bangham AD, Standish MM, Watkins JC. Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol 1965; 13:238-252
69. Lasic DD. Liposomes: from physics to applications. Amsterdam: Elsevier; 1993
70. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 2005; 4:145-160
71. Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev 2013; 65:36-48
72. Prabhakar U, Maeda H, Jain RK, Sevick-Muraca EM, Zamboni W, Farokhzad OC, et al. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res 2013; 73:2412-2417
73. Gabizon A, Dagan A, Goren D, Barenholz Y, Fuks Z. Liposomes as in vivo carriers of adriamycin: reduced cardiac uptake and preserved antitumor activity in mice. Cancer Res 1982; 42:4734-4739
74. Juliano RL, Stamp D. The effect of particle size and charge on the clearance rates of liposomes and liposome encapsulated drugs. Biochem Biophys Res Commun 1975; 63:651-658
75. Poste G, Bucana C, Raz A, Bugelski P, Kirsh R, Fidler IJ. Analysis of the fate of systemically administered liposomes and implications for their use in drug delivery. Cancer Res 1982; 42:1412-1422
76. Woodle MC, Lasic DD. Sterically stabilized liposomes. Biochim Biophys Acta 1992; 1113:171-199
77. Lasic D, Martin F, Gabizon A, Huang S, Papahadjopoulos D. Sterically stabilized liposomes: a hypothesis on the molecular origin of the extended circulation times. Biochim Biophys Acta 1991; 1070:187-192
78. Gabizon A, Papahadjopoulos D. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc Natl Acad Sci USA 1988; 85:6949-6953
79. Klibanov AL, Maruyama K, Beckerleg AM, Torchilin VP, Huang L. Activity of amphipathic poly(ethylene glycol) 5000 to prolong the circulation time of liposomes depends on the liposome size and is unfavorable for immunoliposome binding to target. Biochim Biophys Acta 1991; 1062:142-148
80. Gabizon AA. Liposome circulation time and tumor targeting: implications for cancer chemotherapy. Adv Drug Deliv Rev 1995; 16:285-294
81. Cullis PR, Hope MJ, Bally MB, Madden TD, Mayer LD, Fenske DB. Influence of pH gradients on the transbilayer transport of drugs, lipids, peptides and metal ions into large unilamellar vesicles. Biochim Biophys Acta 1997; 1331:187-211
82. Barenholz Y. Liposome application: problems and prospects. Curr Opin Colloid Interface Sci 2001; 6:66-77
83. Immordino ML, Dosio F, Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine 2006; 1:297-315
84. Allen TM, Hansen C. Pharmacokinetics of stealth versus conventional liposomes: effect of dose. Biochim Biophys Acta 1991; 1068:133-141
85. Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal doxorubicin. Clin Pharmacokinet 2003; 42:419-436
86. Swenson CE, Perkins WR, Roberts P, Janoff AS. Liposome technology and the development of Myocet (liposomal doxorubicin citrate). Breast 2001; 10:1-7
87. Alberts DS, Muggia FM, Carmichael J, Winer EP, Jahanzeb M, Venook AP, et al. Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials. Semin Oncol 2004; 31:53-90
88. Wood BJ, Poon RT, Locklin JK, Dreher MR, Ng KK, Eugeni M, et al. Phase I study of heat-deployed liposomal doxorubicin during radiofrequency ablation for hepatic malignancies. J Vasc Interv Radiol 2012; 23:248-55 e7
89. Zagar TM, Vujaskovic Z, Formenti S, Rugo H, Muggia F, O'Connor B, et al. Two phase I dose-escalation/pharmacokinetics studies of low temperature liposomal doxorubicin (LTLD) and mild local hyperthermia in heavily pretreated patients with local regionally recurrent breast cancer. Int J Hyperthermia 2014; 30:285-294
90. Swenson CE, Bolcsak LE, Batist G, Guthrie TH Jr, Tkaczuk KH, Boxenbaum H, et al. Pharmacokinetics of doxorubicin administered iv as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer. Anticancer Drugs 2003; 14:239-246
91. Kanter PM, Bullard GA, Ginsberg RA, Pilkiewicz FG, Mayer LD, Cullis PR, et al. Comparison of the cardiotoxic effects of liposomal doxorubicin (TLC D-99) versus free doxorubicin in beagle dogs. In Vivo 1993; 7:17-26
92. Toldo S, Goehe RW, Lotrionte M, Mezzaroma E, Sumner ET, Biondi-Zoccai GG, et al. Comparative cardiac toxicity of anthracyclines in vitro and in vivo in the mouse. PLoS One 2013; 8:e58421
93. Mayer LD, Bally MB, Cullis PR, Wilson SL, Emerman JT. Comparison of free and liposome encapsulated doxorubicin tumor drug uptake and antitumor efficacy in the SC115 murine mammary tumor. Cancer Lett 1990; 53:183-190
94. Harris L, Batist G, Belt R, Rovira D, Navari R, Azarnia N, et al. Liposomeencapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer 2002; 94:25-36
95. Batist G, Ramakrishnan G, Rao CS, Chandrasekharan A, Gutheil J, Guthrie T, et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 2001; 19:1444-1454
96. Van Dalen EC, Michiels EM, Caron HN, Kremer LC. Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev 2010; Issue 5, Art. No.: CD005006
97. Cortes J, Di Cosimo S, Climent MA, Cortés-Funes H, Lluch A, Gascón P, et al. Nonpegylated liposomal doxorubicin (TLC-D99), paclitaxel, and trastuzumab in HER-2-overexpressing breast cancer: a multicenter phase I/II study. Clin Cancer Res 2009; 15:307-314
98. Baselga J, Manikhas A, Cortés J, Llombart A, Roman L, Semiglazov VF, et al. Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer. Ann Oncol 2014; 25:592-598
99. Gabizon A, Shiota R, Papahadjopoulos D. Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulation times. J Natl Cancer Inst 1989; 81:1484-1488
100. Working P, Dayan A. Pharmacological-toxicological expert report. CAELYX (Stealth liposomal doxorubicin HCl). Hum Exp Toxicol 1996; 15:751-785
101. Siegal T, Horowitz A, Gabizon A. Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model:biodistribution and therapeutic efficacy. J Neurosurg 1995; 83:1029-1037
102. Gabizon AA, Barenholz Y, Bialer M. Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethylene glycolderivatized phospholipid: pharmacokinetic studies in rodents and dogs. Pharm Res 1993; 10:703-708
103. Amantea M, Newman M, Sullivan T, Forrest A, Working P. Relationship of dose intensity to the induction of palmar-plantar erythrodysesthia by pegylated liposomal doxorubicin in dogs. Hum Exp Toxicol 1999; 18:17-26
104. Gabizon A, Tzemach D, Mak L, Bronstein M, Horowitz AT. Dose dependency of pharmacokinetics and therapeutic efficacy of pegylated liposomal doxorubicin (DOXIL) in murine models. J Drug Target 2002; 10:539-548
105. Gabizon A, Catane R, Uziely B, Kaufman B, Safra T, Cohen R, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 1994; 54:987-992
106. Northfelt DW, Martin FJ, Working P, Volberding PA, Russell J, Newman M, et al. Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma. J Clin Pharmacol 1996; 36:55-63
107. Symon Z, Peyser A, Tzemach D, Lyass O, Sucher E, Shezen E, et al. Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes. Cancer 1999; 86:72-78
108. Hobbs SK, Monsky WL, Yuan F, Roberts WG, Griffith L, Torchilin VP, et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci USA 1998; 95:4607-4612
109. Hashizume H, Baluk P, Morikawa S, McLean JW, Thurston G, Roberge S, et al. Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 2000; 156:1363-1380
110. Vail DM, Amantea MA, Colbern GT, Martin FJ, Hilger RA, Working PK. Pegylated liposomal doxorubicin: proof of principle using preclinical animal models and pharmacokinetic studies. Semin Oncol 2004; 31:16-35
111. Gabizon A, Martin F. Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours. Drugs 1997; 54 (Suppl 4):15-21
112. Gabizon A, Tzemach D, Mak L, Bronstein M, Horowitz AT. Dose dependency of pharmacokinetics and therapeutic efficacy of pegylated liposomal doxorubicin (DOXIL) in murine models. J Drug Target 2002; 10:482-539
113. Papahadjopoulos D, Allen TM, Gabizon A, Mayhew E, Matthay K, Huang SK, et al. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci USA 1991; 88:11460-11464
114. Working PK, Newman MS, Huang SK, Mayhew E, Vaage J, Lasic DD. Pharmacokinetics, biodistribution and therapeutic efficacy of doxorubicin encapsulated in Stealth liposomes (Doxil). J Liposome Res 1994; 4:667-687
115. Vaage J, Barberá?Guillem E, Abra R, Huang A, Working P. Tissue distribution and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts. Cancer 1994; 73:1478-1484
116. Vaage J, Donovan D, Uster P, Working P. Tumour uptake of doxorubicin in polyethylene glycol-coated liposomes and therapeutic effect against a xenografted human pancreatic carcinoma. Br J Cancer 1997; 75:482-486
117. O'Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004; 15:440-449
118. Safra T, Muggia F, Jeffers S, Tsao-Wei DD, Groshen S, Lyass O, et al. Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. Ann Oncol 2000; 11:1029-1033
119. Gill SE, Savage K, Wysham WZ, Wysham WZ, Blackhurst DW, Winter WE, Puls LE. Continuing routine cardiac surveillance in long-term use of pegylated liposomal doxorubicin: is it necessary? Gynecol Oncol 2013; 129:544-547
120. Yildirim Y, Gultekin E, Avci ME, Inal MM, Yunus S, Tinar S. Cardiac safety profile of pegylated liposomal doxorubicin reaching or exceeding lifetime cumulative doses of 550 mg/m2 in patients with recurrent ovarian and peritoneal cancer. Int J Gynecol Cancer 2008; 18:223-227
121. Grenader T, Goldberg A, Gabizon A. Monitoring long-term treatment with pegylated liposomal doxorubicin: how important is intensive cardiac followup?.Anticancer Drugs 2010; 21:868-871
122. Andreopoulou E, Gaiotti D, Kim E, Downey A, Mirchandani D, Hamilton A, et al. Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil): experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer. Ann Oncol 2007; 18:716-721
123. Berry GBM, Alderman E, Richardson P, Torti F, Lum B, Patek A, Martin FJ. The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin. Ann Oncol 1998; 9:711-716
124. Gabizon AA, Lyass O, Berry GJ, Wildgust M. Cardiac safety of pegylated liposomal doxorubicin (Doxil/Caelyx) demonstrated by endomyocardial biopsy in patients with advanced malignancies. Cancer Invest 2004; 22:663-669
125. Uziely B, Jeffers S, Isacson R, Kutsch K, Wei-Tsao D, Yehoshua Z, et al. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol 1995; 13:1777-1785
126. Lyass O, Uziely B, Ben-Yosef R, Tzemach D, Heshing NI, Lotem M, et al. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer 2000; 89:1037-1047
127. Lotem M, Hubert A, Lyass O, Goldenhersh MA, Ingber A, Peretz T, et al. Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin. Arch Dermatol 2000; 136:1475-1480
128. Gabizon A, Isacson R, Rosengarten O, Tzemach D, Shmeeda H, Sapir R. An open-label study to evaluate dose and cycle dependence of the pharmacokinetics of pegylated liposomal doxorubicin. Cancer Chemother Pharmacol 2008; 61:695-702
129. Gabizon A, Muggia FM. Initial clinical evaluation of pegylated liposomal doxorubicin in solid tumors. In: Woodle M, Storm G, editors. Longcirculating liposomes: old drugs, new therapeutics. Austin, Texas: Landes Bioscience; 1998. pp. 165-174
130. Solomon R, Gabizon AA. Clinical pharmacology of liposomal anthracyclines: focus on pegylated liposomal Doxorubicin. Clin Lymphoma Myeloma 2008; 8:21-32
131. Szebeni J, Muggia F, Gabizon A, Barenholz Y. Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products:prediction and prevention. Adv Drug Deliv Rev 2011; 63:1020-1030
132. Chanan-Khan A, Szebeni J, Savay S, Liebes L, Rafique NM, Alving CR, et al. Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions. Ann Oncol 2003; 14:1430-1437
133. Cannon TL, Lai DW, Hirsch D, Delacure M, Downey A, Kerr AR, et al. Squamous cell carcinoma of the oral cavity in nonsmoking women: a new and unusual complication of chemotherapy for recurrent ovarian cancer?.Oncologist 2012; 17:1541-1546
134. Bonomi MR, Misiukiewicz K, Posner M, Maki RG. Squamous cell carcinoma of the oral tongue in two patients previously exposed to long-term pegylated liposomal doxorubicin. Oncologist 2012; 17:1594-1595
135. Kwa M, Baumgartner R, Shavit L, Barash I, Michael J, Puzanov I, et al. Is renal thrombotic angiopathy an emerging problem in the treatment of ovarian cancer recurrences?. Oncologist 2012; 17:1534-1540
136. Lao J, Madani J, Puertolas T, Alvarez M, Hernandez A, Pazo-Cid R, et al. Liposomal doxorubicin in the treatment of breast cancer patients: a review. J Drug Delivery 2013; 2013:12
137. Chia S, Clemons M, Martin LA, Rodgers A, Gelmon K, Pond GR, et al. Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial. J Clin Oncol 2006; 24:2773-2778
138. Wolff AC, Wang M, Li H, Pins MR, Pretorius FJ, Rowland KM, et al. Phase II trial of pegylated liposomal doxorubicin plus docetaxel with and without trastuzumab in metastatic breast cancer: Eastern Cooperative Oncology Group trial E3198. Breast Cancer Res Treat 2010; 121:111-120
139. Collea RP, Kruter FW, Cantrell JE, George TK, Kruger S, Favret AM, et al. Pegylated liposomal doxorubicin plus carboplatin in patients with metastatic breast cancer: a phase II study. Ann Oncol 2012; 23:2599-2605
140. Martin M, Sanchez-Rovira P, Munoz M, Baena-Canada JM, Mel JR, Margeli M, et al. Pegylated liposomal doxorubicin in combination with cyclophosphamide and trastuzumab in HER2-positive metastatic breast cancer patients: efficacy and cardiac safety from the GEICAM/2004-05 study. Ann Oncol 2011; 22:2591-2596
141. Anton A, Ruiz A, Plazaola A, Calvo L, Segui MA, Santaballa A, et al. Phase II clinical trial of liposomal-encapsulated doxorubicin citrate and docetaxel, associated with trastuzumab, as neoadjuvant treatment in stages II and IIIA HER2-overexpressing breast cancer patients. GEICAM 2003-03 study. Ann Oncol 2011; 22:74-79
142. Rayson D, Suter TM, Jackisch C, Van Der Vegt S, Bermejo B, Van den Bosch J, et al. Cardiac safety of adjuvant pegylated liposomal doxorubicin with concurrent trastuzumab: a randomized phase II trial. Ann Oncol 2012; 23:1780-1788
143. Shmeeda H, Tzemach D, Mak L, Gabizon A. Her2-targeted pegylated liposomal doxorubicin: retention of target-specific binding and cytotoxicity after in vivo passage. J Control Release 2009; 136:155-160
144. Hendriks BS, Klinz SG, Reynolds JG, Espelin CW, Gaddy DF, Wickham TJ. Impact of tumor HER2/ERBB2 expression level on HER2-targeted liposomal doxorubicin-mediated drug delivery: multiple low-affinity interactions lead to a threshold effect. Mol Cancer Ther 2013; 12:1816-1828
145. Reynolds JG, Geretti E, Hendriks BS, Lee H, Leonard SC, Klinz SG, et al. HER2-targeted liposomal doxorubicin displays enhanced anti-tumorigenic effects without associated cardiotoxicity. Toxicol Appl Pharmacol 2012; 262:1-10
146. Hendriks B, Shields A, Siegel B, Miller K, Munster P, Ma C, et al. 55PPET/CT imaging of 64CU-labelled HER2 liposomal doxorubicin (64CU-MM-302) quantifies variability of liposomal drug delivery to diverse tumor lessions in HER2-positive breast cancer patients. Ann Oncol 2014; 25:i19